sensitive than DS-ELISA but there was no demonstrable difference in the specificity or reproducibility between the two assays.
The ISAGA is suitable for the diagnosis of acute toxoplasmosis in immunocompetent patients and as a screening test for recent infection in pregnant women. The persistence of ISAGA reactivity, however, is such that additional serological assessment is required to define the risk of congenital infection.
Acute toxoplasma infection in immunocompetent patients is usually asymptomatic. The few who develop a clinical illness present with non-specific signs and symptoms such as malaise and lymphadenopathy.' In clinical practice the diagnosis of toxoplasmosis is based on serological findings. Measurement of specific IgM antibody is of known value,2 and several detection methods have been developed, including the indirect immunofluorescent antibody test (IFAb),3 latex agglutination assay,4 and the enzyme linked immunosorbent assay (ELISA). 5 The double sandwich enzyme linked immunosorbent assay (DS-ELISA) has been shown to be more sensitive than IFAb or conventional ELISA methods.6 Furthermore, the initial y chain capture reduces the incidence offalse negative reactions associated with the presence of excess toxoplasma IgG and false positive results due to rheumatoid factor or antinuclear antibody which are known hazards of the conventional ELISA or IFAb test.7
The IgM latex agglutination assay, IFAb test, ELISA and DS-ELISA use disrupted toxoplasma organisms as an antigen source. French workers have proposed that toxoplasma serology tests should use whole toxoplasma trophozoites as antigens.! They suggest that the presentation of the organism in its Accepted for publication 28 July 1989 entirety is an accurate reflection of the antigenic stimulation of the immune system induced in acute infection. Consequently, assays based on whole toxoplasma trophozoites may prove superior for the detection of the human antibody response in toxoplasmosis. The immunoglobulin-M immunosorbent agglutination assay (ISAGA) is routinely used in France for the diagnosis of acute toxoplasmosis and congenital infection.8 This assay uses a monoclonal antibody to the CH2 domain of the human p chain, allowing IgM capture, while avoiding cross reactivity with IgG, IgA, or IgE.9 Specific IgM is then shown by the agglutination ofwhole toxoplasma trophozoites.'°A s the ISAGA has recently become available in this country we undertook a study to compare the performance of this assay with that of the DS-ELISA currently used in our laboratory for detection of toxoplasma specific IgM.
Material and methods
The immunosorbent agglutination assay (ISAGA) detects human IgM antibodies to toxoplasma. An anti-human IgM monoclonal antibody is used to capture human IgM in serum or cerebrospinal fluid. The addition of toxoplasma trophozoites shows the presence of specific toxoplasma IgM.
The kit consists of a 4 ml suspension of formalin treated Toxoplasma gondii trophozoites obtained 1292 from mouse ascitic fluid, 80 ml of diluent (BABS colour buffer), 0 5 ml positive control sera, powdered phosphate buffered saline (PBS) sufficient for 2 litres, and 1 ml of Tween 20. Also included are four report sheets and four sachets each containing six strips of 2 x 8 round base wells, sensitised with anti-human IgM monoclonal antibody, presented in a microtitre format. The shelf life of this ISAGA kit is said to be six months at 4°C.
The manufacturers suggest a screening procedure followed by a confirmatory test performed only on positive samples. In this trial a single assay was performed. Each serum sample was placed in three wells to which were added 100, 150, or 200 il of antigen suspension. Sera were diluted at 1/100 in PBS, except those for neonates which were diluted at 1/20. The positive control serum was diluted at 1/10. PBS alone was used as a negative control. Each serum dilution (100 Ml) was placed into three adjacent wells.
The strips were then covered and incubated at 37°C in a moist chamber for two hours. After incubation the wells were emptied by inverting the plate. Each well was washed twice in PBS-Tween and once in PBS alone. The plate was drained thoroughly by tapping on clean paper towels. The toxoplasma antigen was diluted to 1/20 with BABS buffer and added to the wells, as previously described. The strips were then covered, placed in a moist chamber, and left at 370 overnight. Agglutination patterns were determined using a mirrored plate reader.
A negative reaction resulted in sedimentation of the toxoplasma trophozoites forming a compact button. The results were marked on a scale of 0 to 4. Total sedimentation in a button similar to the antigen (negative) control, with no agglutination, was given a value of 0, a large button a value of 1, medium sized button 2, very small button 3, and no visible sediment 4. Each well was scored and the total for the three wells was called the "ISAGA index". The ISAGA index was interpreted as follows: 0 to 5, negative reaction; 6 to 8, borderline; 9 to 12, positive reaction.
Methods for the DS-ELISA," the dye test (DT),'2 latex agglutination test (LAT),'3 and direct agglutination test (DAT)'4 were used as previously described. Toxoplasma specific IgM measurements were performed on routine serum samples producing a DT result of > 31 units, or when the DAT or LAT findings were suggestive of acute infection. ISAGA and DS-ELISA were also performed on samples from patients who were human immunodeficiency virus (HIV) positive, transplant recipients or who suffered from retinochoroiditis, and mother and baby samples in cases of possible congenital infection.
The results of the ISAGA and DS-ELISA were defined in the following way: if both assays were positive IgM was positive; if both were negative IgM Duffy, Wharton, Johnson, New, Holliman was negative. Where one assay gave positive results and the other negative these were termed "mismatches". Both assays were then repeated. Where one assay produced a borderline or equivocal result and the other a clear positive or negative result, these were not regarded as "mismatches".
The sensitivity, specificity, and reproducibility of the tests were assessed using separate selected sera. Five sera showing high DS-ELISA results (300-400 enzyme immunoassay units (EIU)) were diluted sequentially in physiological saline to produce a 10% dilution sequence and each dilution tested for specific IgM An ISAGA test run had to be repeated when the positive control read less than nine or the negative control produced a positive result. In no instance did the tests need repeating for these reasons. Out of 14 kits used, however, four strips seemed to be defective. If there was obvious discrepancy between the three ISAGA wells used for any one sample it was repeated. This occurred in 1% of tests performed.
There were 16 instances where a series of sera were received on a particular patient. The initial serum result only was included in the figures in the table. Of these 16 series, nine showed loss of DS-ELISA reactivity first and four series showed loss of ISAGA reactivity at a time when DS-ELISA reactivity persisted.
The cost of performing the ISAGA test was about £L-30 a sample. Used as a screening test, as described by the manufacturer, the cost would be 90p a sample. The DS-ELISA is not available commercially and is produced "in house" at the Toxoplasma Reference Laboratory, Swansea. There are, however, several similar p chain capture ELISA assays available on a commercial basis. The ISAGA test was found to be technically easier to perform than the DS-ELISA. It required only a mirrored plate reader as additional equipment. The DS-ELISA required an optical scanner, a method of data analysis (usually computerised), and accurate dilution equipment, preferably mechanical. The technical time required for performing each test was estimated at three minutes a sample for the DS-ELISA and two minutes a sample for the ISAGA, based on a batch run of 40 specimens.
Discussion
The dye test originated by Sabin and Feldman is the accepted reference assay used for the diagnosis of toxoplasmosis. This test measures both IgG and IgM antibodies, but a positive reaction does not delineate the immunoglobulin class. Although the dye test can be used as a reference value when assessing assays predominantly measuring toxoplasma specific IgG, it is of less value in the context of IgM detection. '4 Samples showing a seroconversion from negativity to positivity are available in limited numbers only and the non-specific signs and symptoms of acute toxoplasmosis make diagnosis based on clinical findings unreliable.'5 Analysis of antibody response using Western blots has failed to determine criteria for the diagnosis of acute toxoplasmosis'6 while antigen detection and DNA probing techniques remain at the developmental stage. Isolation of the parasite from clinical samples does not differentiate acute from chronic infection. Consequently, there is no definitive reference to which toxoplasma IgM tests may be compared and calculation of predictive values or percentage figures for sensitivity and specificity is not justified.
Although both assay results were most often in agreement, the commonest finding in a confirmed mismatch was that of a positive ISAGA reaction in a sample negative by DS-ELISA testing. Our findings of persistence of ISAGA reactivity at higher serum dilutions and a greater period of time after acquisition of infection than by DS-ELISA suggest a proportion of discordant results will reflect the greater sensitivity of the former assay. Other groups have shown that ISAGA exhibits superior sensitivity compared with commercial ELISA systems'7 or immunofluorescent antibody techniques.'8 French workers found that 80% of patients maintained a positive ISAGA reaction one year after infection compared with 40% positive by commercial ELISA. '7 In clinical practice toxoplasmosis is often considered only when more familiar disease processes have been excluded. Consequently, ISAGA would be useful for the investigation of suspected toxoplasmosis, particularly when the diagnosis is postulated late in the course of the infection.
Experience of ISAGA in Scotland has shown the persistence of reactivity into the second pregnancy following the birth of a congenitally infected infant. '9 The risk of the parasite passing from mother to fetus rises as the pregnancy progresses but the severity of any subsequent infection falls. Chronic latent toxoplasma infection of the mother poses no risk of congenital toxoplasmosis.' Although little data are available, it is thought that toxoplasmosis acquired before pregnancy will only result in congenital infection if parasitaemia persists at the time of conception. The duration of parasitaemia after the acquisition of infection is uncertain and is likely to vary both with the virulence of the parasite and the susceptibility of the host. Consequently the risk of fetal infection when conception occurs after the acquisition of toxoplasmosis, but at a time when specific IgM can be detected by a highly sensitive assay, such as ISAGA, has not been defined. Further studies are required so that suitable advice may be offered to pregnant women who produce a positive ISAGA reaction. Until such studies are completed, the investigation of these patients must. include additional serological assessment. We are indebted to Mrs I Crossman for her secretarial assistance.
